# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated fr...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for Q2-2024, its unaudited revenues have grow...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into a distribution agreement with C...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that continued revenue growth generated cash levels...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into an agreement with a Japanese di...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that Q3-2023 (unaudited) revenues have increased 2...